A new study published in the Journal of Autoimmunity reveals the role of macrophages in response to Ahead Therapeutics’ MiMiTOP (Mimicking Tolerogenic Particles) in Type 1 Diabetes (T1D). The researchers from IGTP (Germans Trias i Pujol Research Institute) and Ahead Therapeutics, in collaboration with Sant Pau Research Institute and Sartorius Stedim, have demonstrated that, upon MiMiTOP administration, macrophages are the most phagocytic cell subset in the spleen and liver, underscoring their importance in the tolerogenic effect of the particles.
The study also confirmed that altered immune activity in T1D does not interfere with the ability of macrophages to uptake the particles and undergo a subsequent tolerogenic profile switch. Particularly, the inflammatory subset of macrophages has normalized their marker expression and reduced pro-inflammatory cytokine secretion upon MiMiTOP uptake.
In summary, these results affirm the advantages of MiMiTOP in promoting immune tolerance in T1D and underpin the understanding of the mechanism behind this preclinical immunotherapy.
Reference
Garcia-Loza I, Perna-Barrull D, Aguilera E, Almenara-Fuentes L, Gomez-Muñoz L, Greco D, Vila M, Salvado M, Mancera-Arteu M, Olszowy MW, Petriz J, Dalmases M, Rodriguez-Vidal S, Barneda-Zahonero B, Vives-Pi M. Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes. J Autoimmun. 2024 Mar 7;145:103196. DOI: 10.1016/j.jaut.2024.103196.